DHLAX | VIVAX | DHLAX / VIVAX | |
Total Expense Ratio | 0.96 | 0.17 | 565% |
Annual Report Gross Expense Ratio | 0.96 | 0.17 | 565% |
Fund Existence | 24 years | 33 years | - |
Gain YTD | 5.057 | 6.724 | 75% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2500 | 3000 | 83% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 8.43B | 195B | 4% |
Annual Yield % from dividends | 1.04 | 2.06 | 50% |
Returns for 1 year | -0.97 | 9.76 | -10% |
Returns for 3 years | 15.76 | 34.31 | 46% |
Returns for 5 years | 33.96 | 74.87 | 45% |
Returns for 10 years | 59.28 | 116.32 | 51% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
PARWX | 57.32 | 0.30 | +0.53% |
Parnassus Value Equity Investor | |||
GILLX | 23.90 | 0.10 | +0.42% |
Goldman Sachs Enhanced U.S. Equity Inst | |||
VECRX | 22.33 | 0.07 | +0.31% |
Virtus KAR Equity Income R6 | |||
NZDCHF | 0.48 | 0.00 | +0.21% |
New Zealand Dollar - Switzerland Franc | |||
FBTIX | 30.97 | N/A | N/A |
Fidelity Advisor Biotechnology I |